Permixon, benign prostatic hyperplasia

Unfortunately, not all products that are used in clinical trials are available in the United States. In a randomized, double-blind, multicenter European study, 1069 men with moderate benign prostatic hyperplasia were randomized to receive saw palmetto (Permixon" )1 160 mg twice daily (90% free and 7% esterified fatty acids) or finasteride 5 mg once daily for 6 months [32]. As determined by patients and physicians, Permixon offered similar improvement in symptoms related to benign prostatic hyperplasia compared to finasteride. Since Permixon is not available in the United States, it should be recommended to patients to use a product that is similar to Permixon that contains a standardized extract of saw palmetto containing 85-95% sterols and fatty acids [18]. 

Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia a randomized international study of 1098 patients. Prostate 4 231-240, 1996. 

Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9(5) 379-395, 1996. 

Kuzmin, and R. R. Amdiy. Early urodynamic effects of the lipido-ste-rolic extract of Serenoa repens (Permixon ) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2000 3(3) 195-199. 

SR014 Debruyne, F., G. Koch, P. Boyle, et al., and the Groupe d etude PERMAL. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia a 1 -year randomized international study. Prog Urol 2002 12(3) 384-392. 

SR024 Vacherot, F., M. Azzouz, S. Gil-Diez-De-Medina, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon) in benign prostatic hyperplasia. Prostate 2000 45(3) 259-266. 

Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia a randomized international study of 1,098 patients. Prostate I996 29(4) 23 I K). 

Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon ), tamsulosin or finasteride. Eur Urol 2005 48 269-76. 

Pygeum africanum and Permixon for the Treatment of Patients with Benign Prostatic Hyperplasia... 

PERMIXON IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA... 

Boyle, P. et al., Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia, Urology, 55, 533-539, 2000. 

Permixon (liposterolic extract) (fatty acids terpenes) Serenoa repens (Palmae) 5aR (6ng/L) (AND-R) [treatment of benign prostatic hyperplasia due to dihydrotestosterone accumulation for breast enlargement]... 

Briley M, Carilla E. Fauran F. Permixon, a new treatment for benign prostatic hyperplasia, acts directly at the cytosolic androgen receptor in rat prostate [abstract]. Br J Pharmacol 1983 79 327P. 

Carilla E, Briley M, Fauran F, et al. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 20 521-523, 1984. 

---